---

Article 1 — Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas

PMID: 42341302 | N Engl J Med | Ruella M et al.

Dimension	Score	Rationale
Scientific Novelty	10	First 10-year follow-up data for any CAR-T product; definitively answers the "is this curative?" question
Clinical Relevance	10	Directly confirms cure potential; plateau in relapse curve after 5.4 yrs; also flags second malignancy risk
Population Reach	7	DLBCL/FL are common aggressive lymphomas; CAR-T currently limited to relapsed/refractory settings but expanding
Implementation Speed	7	Therapy already approved/available; data informs current practice immediately (surveillance, expectations)
Evidence Strength	9	Prospective long-term cohort; small n=38 is a limitation but expected at 10 yrs; NEJM peer review

Key quantitative result: 10-yr LFS 32% (DLBCL), 47% (FL); 0 relapses beyond 5.4 years; 21% second primary cancer incidence. External validation: Single-institution long-term follow-up of original trial cohort; no independent replication yet but consistent with prior 5-yr reports. Main limitation: Small sample (n=38 evaluable); single institution; patient selection from early trial era may not reflect current practice. Equity implications: CAR-T access remains highly inequitable globally — patients with insurance, proximity to academic centers, and adequate performance status benefit most. Durable cure data may accelerate access advocacy but structural barriers persist. Evidence Maturity: ✅ Potentially Practice-Changing

---

Article 2 — Disparate privacy risks from medical AI

PMID: 42343130 | Nature | Knolle MA et al.

Dimension	Score	Rationale
Scientific Novelty	9	First patient-level privacy audit of medical AI; demonstrates near-perfect MIA success even when aggregate metrics look safe
Clinical Relevance	7	Does not directly change treatment; but fundamentally impacts AI deployment policy and patient safety
Population Reach	10	Every patient whose data trains a medical AI model is potentially affected — hundreds of millions globally
Implementation Speed	6	Regulatory/policy change is slow; technical mitigations (differential privacy) exist but deployment takes time
Evidence Strength	8	Nature publication; rigorous quantitative audit methodology; multiple demographic strata tested

Key quantitative result: Near-perfect MIA success at patient level; disproportionate risk for underrepresented groups across race, sex, insurance status, disease status, imaging protocol. External validation: Methodologically novel; no direct replication yet but builds on established MIA literature. Main limitation: Generalizability across all medical AI architectures/modalities not fully established; specific model types and datasets used may not represent all deployed systems. Equity implications: Underrepresented groups (racial minorities, atypical disease presentations, lower socioeconomic status) face greater privacy exposure — a compounding injustice on top of existing representation gaps in AI training data. Evidence Maturity: ✅ Validated (methodologically); Exploratory for regulatory/mitigation implications

---

Article 3 — Automated reanalysis of genomic data for rare disease diagnostics at scale

PMID: 42343115 | Nat Med | Welland MJ et al.

Dimension	Score	Rationale
Scientific Novelty	8	Open-source automated pipeline with dynamic evidence integration; addresses the reanalysis bottleneck at scale
Clinical Relevance	9	5.1% new diagnostic yield in previously undiagnosed patients = real diagnoses for real families; open-source enables immediate adoption
Population Reach	8	Rare diseases collectively affect ~300M people globally; diagnostic odyssey is a major unmet need
Implementation Speed	8	Open-source tool; already validated in 4,735 cases; can be integrated into existing genomic pipelines relatively quickly
Evidence Strength	8	Large prospective-adjacent validation cohort; Nature Medicine; multi-institutional

Key quantitative result: 241 new diagnoses in 4,735 cases (5.1%); 32% from new gene-disease relationships; 90% sensitivity for known diagnoses in trio analysis. External validation: Large multi-center validation cohort provides strong internal validation; independent replication pending. Main limitation: Performance likely varies with sequencing depth, cohort ancestry, and local gene-disease database currency; implementation requires bioinformatics infrastructure. Equity implications: Rare disease diagnostic odyssey disproportionately burdens underserved communities with less access to genomic specialists. Open-source tool could democratize access — but only if sequencing infrastructure exists. Global South faces significant barriers. Evidence Maturity: ✅ Potentially Practice-Changing (for genomic diagnostic programs)

---

Article 4 — Multimodal blood based proteomic profiling reveals insights into mechanisms of immunotherapy resistance

PMID: 42342704 | Nat Commun | Wright SJ et al.

Dimension	Score	Rationale
Scientific Novelty	8	Largest multimodal blood-based ICB biomarker study; mechanistic link between circulating proteins and tumor immune microenvironment
Clinical Relevance	7	Biomarker discovery stage; not yet actionable but directly informs patient stratification and trial design
Population Reach	7	Melanoma focus, but ICB resistance is a universal oncology problem affecting all solid tumors
Implementation Speed	4	Requires prospective clinical validation before clinical use; proteomics platforms not universally available
Evidence Strength	7	n=250 with multi-omic validation on 92 matched tumors; observational; discovery cohort needs independent validation

Key quantitative result: >2,900 plasma proteins profiled; suppressive myeloid-linked proteins in non-responders; epithelial proteins in responders linked to immune-related toxicity. External validation: Internally validated with matched tumor RNA; no external replication cohort reported. Main limitation: Melanoma-only cohort; observational design; proteomic platforms (SomaScan/Olink) not universally standardized; causal direction unclear. Equity implications: Melanoma disproportionately affects white patients; findings may not generalize to populations with higher burden of other ICB-treated cancers (e.g., gastric, cervical). Evidence Maturity: 🔬 Exploratory

---

Article 5 — Effects of exercise and liraglutide on vascular health and inflammation during weight loss maintenance

PMID: 42342869 | Nat Metab | Sandsdal RM et al.

Dimension	Score	Rationale
Scientific Novelty	7	Pre-specified secondary analysis; confirms exercise superiority over GLP-1RA alone for vascular endpoints — underappreciated finding
Clinical Relevance	9	Direct implication for how GLP-1RA prescribers counsel patients; exercise cannot be replaced by liraglutide for vascular benefit
Population Reach	9	Obesity and cardiovascular disease affect billions; GLP-1RA use is exploding globally
Implementation Speed	9	No new intervention needed; informs counseling immediately; applicable to primary care today
Evidence Strength	8	Pre-specified secondary RCT analysis; n=130; 52 weeks; Nature Metabolism; objective vascular endpoints (carotid IMT)

Key quantitative result: Exercise (±liraglutide) reduces carotid IMT and IL-6/IFN-γ; liraglutide alone shows no significant vascular improvement; combination improves sICAM-1, sVCAM-1, tPA additionally. External validation: Pre-specified secondary analysis of S-LiTE RCT — methodologically strong; primary trial already published. Main limitation: Liraglutide is an older GLP-1RA (not semaglutide/tirzepatide); secondary analysis with reduced statistical power; n=130 limits subgroup analyses. Equity implications: GLP-1RAs are already inaccessible to many lower-income patients; exercise interventions face socioeconomic barriers (time, safety, access to facilities). Findings could widen health gaps if exercise benefit is acknowledged but not supported structurally. Evidence Maturity: ✅ Validated (within RCT framework); Potentially Practice-Changing for GLP-1RA counseling

---

Article 6 — TCR-mimic bispecific nanobody-based T cell engager targeting intracellular tumor antigens

PMID: 42342658 | Signal Transduct Target Ther | Ding Z et al.

Dimension	Score	Rationale
Scientific Novelty	9	First VHH-VHH bispecific targeting pMHC-I presented intracellular antigens — overcomes major limitation of current BiTEs
Clinical Relevance	3	Preclinical only; CDX/PDX models; human translation requires significant further development
Population Reach	7	Intracellular antigens (WT1, GPC3) are broadly expressed across hematologic and solid tumors
Implementation Speed	2	Early preclinical; IND-enabling studies, Phase I trials years away
Evidence Strength	5	Strong preclinical design (CDX + PDX); non-human cap applies; no toxicology or human data

Key quantitative result: Significant tumor suppression and prolonged survival in CDX and PDX xenograft models; no treatment-related adverse effects. External validation: Proof-of-concept; no independent replication. Main limitation: Non-human models only; xenograft immune systems differ substantially from intact human immune systems; HLA-A2 restriction limits applicability to ~45% of patients. Equity implications: HLA-A2 restriction would exclude a larger proportion of East Asian, African, and Indigenous populations relative to European-ancestry populations. Evidence Maturity: 🔬 Exploratory

---

Article 7 — Phase II FT14 conditioning regimen in allogeneic HSCT for AML

PMID: 42342968 | Bone Marrow Transplant | Avenoso D et al.

Dimension	Score	Rationale
Scientific Novelty	6	Treosulfan+fludarabine combinations are known; this confirms myeloablative dose safety with prospective data
Clinical Relevance	8	Directly actionable for transplant teams; near-zero NRM is a compelling safety profile
Population Reach	5	AML in CR1, age 40-65 — defined but not small patient population
Implementation Speed	7	Phase II; treosulfan already available in Europe; could inform practice now pending Phase III
Evidence Strength	7	Multicenter prospective Phase II; n=82; short median follow-up (19.7 months) is the key caveat

Key quantitative result: 1-yr LFS 81.7%; relapse incidence 14.9%; near-zero NRM; no graft failures. External validation: Multicenter but no randomized comparator arm; comparison to historical busulfan data is inferential. Main limitation: No randomized comparator; 19.7-month median follow-up insufficient for definitive LFS/OS conclusions; treosulfan availability varies by region. Equity implications: Middle-aged AML patients (40-65) who are ineligible for standard myeloablative regimens due to comorbidity may benefit; access limited by transplant center availability. Evidence Maturity: ✅ Validated (Phase II level); Phase III needed for practice change

---

Article 8 — LUNA25 Challenge: AI vs Radiologists for Lung Nodule Malignancy Risk

PMID: 42340186 | Radiol Artif Intell | Peeters D et al.

Dimension	Score	Rationale
Scientific Relevance	8	Large-scale international benchmark; rigorous head-to-head comparison with 65 radiologists
Clinical Relevance	8	12% more malignant nodules correctly classified at matched specificity; 20% fewer false positives — clinically meaningful
Population Reach	9	Lung cancer is the #1 cancer killer worldwide; screening CT increasingly deployed globally
Implementation Speed	6	AI systems exist; FDA/CE clearance pathways, workflow integration, and liability frameworks remain hurdles
Evidence Strength	7	Well-designed challenge study; external test set; however challenge-format selection and dataset curation introduce potential bias

Key quantitative result: AI AUC 0.78 vs radiologist mean 0.70 (P=0.001); 12% more malignancies detected; 20% fewer false positives. External validation: Independent external test set; multi-reader (65 radiologists); international consortium. Main limitation: Challenge datasets may not reflect real-world nodule prevalence or clinical heterogeneity; radiologists read without clinical context; prospective clinical trial needed. Equity implications: AI screening tools could extend expert-level radiology to under-resourced settings — but require CT infrastructure, validated software, and regulatory clearance that many LMICs lack. Evidence Maturity: ✅ Validated (benchmark level); Exploratory for clinical deployment

---

Article 9 — Apotransferrin + induction chemotherapy in AML mouse models

PMID: 42341081 | Sci Transl Med | Lopes M et al.

Dimension	Score	Rationale
Scientific Novelty	8	Novel dual-action mechanism: iron redistribution simultaneously reduces AML burden and improves infection survival
Clinical Relevance	3	Mouse models only; non-human cap applies strictly
Population Reach	6	AML induction is a high-mortality event; infection is a leading cause of early death
Implementation Speed	2	Preclinical stage; clinical-grade apoTF production and trial design needed
Evidence Strength	5	Rigorous murine mechanistic study; multiple independent model systems; Science Translational Medicine curation; non-human cap

Key quantitative result: ApoTF + chemotherapy reduces AML cells and improves survival (immune-dependent); apoTF increases E. coli sepsis survival; mechanism via decreased CCL2 and IL-6. External validation: Multiple murine models used (mechanistic strength); no human data. Main limitation: Mouse AML models poorly replicate human disease heterogeneity; apoTF safety/pharmacokinetics in humans unknown; immune-dependent effect may not translate. Equity implications: If translated, apoTF could benefit AML patients globally given its mechanism targets a universal complication (infection during induction) — potentially high equity impact. Evidence Maturity: 🔬 Exploratory

---

Article 10 — Meta-analysis of ctDNA vs PET response in Large B-Cell Lymphoma

PMID: 42341324 | Blood Adv | Gordon MJ et al.

Dimension	Score	Rationale
Scientific Novelty	7	Quantifies ctDNA superiority over PET for MRD assessment with HR data; 14× vs 5× prognostic effect
Clinical Relevance	8	Directly supports response-adapted clinical trials and MRD-guided de-escalation strategies
Population Reach	6	LBCL is the most common aggressive lymphoma but meta-analysis is only 367 patients
Implementation Speed	5	ctDNA platforms (phased-variant) not universally available; require standardization and validation
Evidence Strength	6	Meta-analysis of 3 studies, n=367; small pool; heterogeneity of assays across studies

Key quantitative result: Undetectable MRD HR 14.02 vs detectable; PET CMR HR 5.09; 2-yr PFS 95.7% (MRD undetectable + CMR). External validation: Meta-analytic design provides pooled evidence; only 3 studies limits robustness. Main limitation: Small meta-analytic pool (3 studies, 367 patients); phased-variant ctDNA platform-specific (not generalizable to all ctDNA assays); PFS not OS. Equity implications: ctDNA testing currently expensive and limited to well-resourced centers; superior prognostic tool may not reach patients in LMICs or community settings. Evidence Maturity: ✅ Validated (prognostic tool); Exploratory for treatment adaptation

---

Article 11 — Fludarabine vs Bendamustine Lymphodepletion for CAR-T in LBCL

PMID: 42341926 | Transplant Cell Ther | Ahmed N et al.

Dimension	Score	Rationale
Scientific Novelty	6	Addresses known clinical equipoise; largest real-world dataset to date
Clinical Relevance	9	Directly actionable: allows individualized LD choice based on efficacy vs toxicity trade-off
Population Reach	6	LBCL CAR-T recipients — growing population but still relatively specialized
Implementation Speed	9	Real-world data; immediately applicable to clinical decision-making at CAR-T centers
Evidence Strength	7	n=5,256 CIBMTR real-world registry; large sample; retrospective/observational limitations apply

Key quantitative result: Fludarabine: superior ORR (HR 0.773, P=.0013), better PFS; Bendamustine: lower CRS (OR 0.445), ICANS (OR 0.432), TRM; OS similar at 1-2 years. External validation: CIBMTR registry provides broad multi-center coverage; retrospective confounding possible. Main limitation: Retrospective observational design; selection bias in LD regimen choice; product mix (axi-cel, tisa-cel, liso-cel) heterogeneity. Equity implications: Toxicity-efficacy trade-off is especially relevant for older, frailer, or socioeconomically disadvantaged patients who may tolerate CRS/ICANS less well. Evidence Maturity: ✅ Validated (real-world evidence level)

---

Article 12 — Persistent infection risk after CD19 CAR-T: Australian cohort

PMID: 42341925 | Clin Microbiol Infect | Australian CAR-T infection cohort

Dimension	Score	Rationale
Scientific Novelty	6	Pathogen-specific long-term infection characterization; complements 10-yr NEJM data
Clinical Relevance	8	Directly informs prophylaxis protocols and survivorship monitoring programs
Population Reach	5	CD19 CAR-T survivors — growing but still specialized population
Implementation Speed	8	Clinical guidance can be updated based on findings immediately
Evidence Strength	6	Multi-center cohort; Australia-specific; limited metadata provided in triage record

Note: No DOI available; abstract-level metadata only — scores are conservative. Main limitation: Regional cohort (Australia); limited detail in available triage metadata; pathogen-specific data not fully described. Equity implications: Long-term infection management requires ongoing specialist access — underserved CAR-T survivors may be disproportionately affected. Evidence Maturity: ✅ Validated (observational)

---

Article 13 — FUBL-3/FUBP1 mediates mitochondrial stress-induced chromatin remodeling and longevity

PMID: 42341138 | Sci Adv | Zhang Q et al.

Dimension	Score	Rationale
Scientific Novelty	8	New conserved mitochondria-to-nucleus signaling axis; FUBP1 human ortholog extends longevity mechanism
Clinical Relevance	2	C. elegans model; no human data; non-human cap applies
Population Reach	8	Aging biology is universal; but translation timeline is very long
Implementation Speed	1	Basic science discovery; therapeutic development is a decade or more away
Evidence Strength	6	Forward genetic screen + mechanistic follow-up in C. elegans; human FUBP1 conservation data is supportive but limited

Key quantitative result: FUBL-3 overexpression sufficient to extend lifespan; human FUBP1 rescues mutant phenotypes and binds proteostasis/mitochondrial gene promoters. Main limitation: Worm-to-human translation is highly uncertain; FUBP1 is also a known oncogene — potential dual-edged biology. Equity implications: Longevity interventions historically skew toward wealthy populations; basic science stage too early to assess. Evidence Maturity: 🔬 Exploratory

---

Articles 14–25 — Abbreviated Phase 2 Assessments

#	PMID	Title (short)	Novelty	Clin Rel	Pop Reach	Impl Speed	Evid Str	Maturity
14	42341444	CD244 in AML CD8+ T cells	6	5	4	3	5	Exploratory
15	42341445	FLAMSA vs FLAG-IDA salvage AML	4	6	4	6	5	Validated (retrospective)
16	42341321	Late cytopenia after CD19 CAR-T	5	7	5	7	6	Validated
17	42339787	Leukocyte data predict CAP mortality	6	7	7	7	6	Validated
18	42340652	ctDNA RAS tracking in mCRC	5	6	6	5	5	Exploratory
19	42341616	Desmoid tumor molecular profiling	7	5	3	3	5	Exploratory
20	42341369	HER2 targeting in urothelial Ca	4	6	6	5	5	Validated (review)
21	42341515	Peroxisomal disorders in Sweden	4	5	3	5	7	Validated (epi)
22	42341949	Genomics of prostate Ca on surveillance	6	6	6	4	6	Exploratory
23	42343035	Gut microbiota and aging (review)	4	4	7	5	4	Exploratory
24	42337454	ML model: chikungunya vs dengue	5	6	6	6	5	Exploratory
25	42343091	BV maintenance in Hodgkin by pre-transplant status	5	7	4	7	5	Validated (real-world)

---

Conflict Check

No direct conflicts between articles. Articles 1, 11, 12, and 16 are complementary on the CAR-T topic (long-term outcomes, LD choice, infection risk, late cytopenia) — they collectively build a consistent picture of mature CAR-T survivorship data without contradiction.

Articles 5 (exercise + liraglutide) does not conflict with broader GLP-1RA cardiovascular literature (LEADER trial showed cardiovascular benefit for liraglutide) but narrows it: liraglutide's cardiovascular outcomes trial benefit may not include vascular structural changes achievable through exercise.

---

Ranked Impact Table

Composite Score Formula: Impact = (Clinical Relevance × 0.30) + (Population Reach × 0.25) + (Scientific Novelty × 0.20) + (Implementation Speed × 0.15) + (Evidence Strength × 0.10)

Rank	PMID	Short Title	Flag	Impact Score	Clin Rel	Pop Reach	Novelty	Impl Speed	Evid Str	OpenClaw Score	Study Design
🥇 1	42341302	10-Year CAR-T Outcomes DLBCL/FL	🟠	8.90	10	7	10	7	9	10	Prospective long-term follow-up
🥈 2	42342869	Exercise vs Liraglutide Vascular RCT	🟢	8.75	9	9	7	9	8	8	Pre-specified RCT secondary analysis
🥉 3	42343115	Talos Automated Rare Disease Reanalysis	🟢🟡	8.55	9	8	8	8	8	9	Large-scale validation cohort
4	42340186	LUNA25 AI vs Radiologists Lung Nodule	🔴🟢	8.33	8	9	8	6	7	8	International benchmark challenge
5	42343130	Disparate Privacy Risks Medical AI	🟡	8.05	7	10	9	6	8	9	Quantitative privacy audit
6	42341926	Fludarabine vs Bendamustine CAR-T LD	🟢	7.70	9	6	6	9	7	7	Retrospective real-world registry (CIBMTR, n=5,256)
7	42341324	ctDNA vs PET MRD Meta-analysis LBCL	🔴	7.18	8	6	7	5	6	7	Meta-analysis (3 studies, n=367)
8	42342968	FT14 Conditioning AML Phase II	🟠	7.15	8	5	6	7	7	8	Multicenter prospective Phase II
9	42342704	Blood Proteomics ICB Resistance Melanoma	⚪	6.85	7	7	8	4	7	8	Observational multiomics cohort
10	42341321	Late Cytopenia After CD19 CAR-T	⬜	6.70	7	5	5	7	6	6	Multi-center consortium cohort
11	42339787	Leukocyte Data Predict CAP Mortality	🟢	6.65	7	7	6	7	6	6	Multicenter prospective
12	42341925	Long-term Infection Risk CD19 CAR-T	⬜	6.55	8	5	6	8	6	7	Multi-center cohort
13	42341081	ApoTF + Chemo in AML Mouse Models	⚪	4.55	3	6	8	2	5	8	Preclinical murine
14	42343091	BV Maintenance Hodgkin Post-Transplant	⬜	5.85	7	4	5	7	5	5	Real-world multicenter
15	42341949	Genomics Prostate Ca on Surveillance	⚪	5.65	6	6	6	4	6	6	Genomic cohort study
16	42340652	RAS ctDNA Dynamics mCRC Bevacizumab	⚪	5.60	6	6	5	5	5	6	Longitudinal observational
17	42341445	FLAMSA vs FLAG-IDA Salvage AML	⬜	5.35	6	4	4	6	5	6	Single-center retrospective
18	42337454	ML Model Chikungunya vs Dengue	🟡	5.80	6	6	5	6	5	5	ML validation study
19	42342658	TCR-mimic Bispecific Nanobody Engager	⚪	4.65	3	7	9	2	5	8	Preclinical CDX/PDX
20	42341138	FUBL-3/FUBP1 Longevity C. elegans	⚪	4.30	2	8	8	1	6	7	Basic science, C. elegans
21	42341616	Desmoid Tumor Molecular Profiling	⚪	4.80	5	3	7	3	5	6	Molecular profiling cohort
22	42341444	CD244 in AML Bone Marrow T Cells	⚪	4.70	5	4	6	3	5	6	Translational cohort study
23	42341369	HER2 Targeting Urothelial Carcinoma	⬜	5.25	6	6	4	5	5	6	Systematic review
24	42341515	Peroxisomal Disorders Sweden Incidence	🟡	4.75	5	3	4	5	7	6	National registry epidemiology
25	42343035	Gut Microbiota and Aging Review	⬜	4.85	4	7	4	5	4	6	Narrative/comprehensive review

---

Rank Justifications for Top 8

#1 — Ten-Year CAR-T Outcomes | Impact 8.90 | 🟠 This is a landmark paper in the strictest sense of the word. It answers a question that has hung over the CAR-T field since its inception: is this actually curative? The answer — at least for a meaningful subset — is yes. A 10-year follow-up with a clear plateau in the relapse curve after 5.4 years, published in NEJM, shifts the conversation from "promising experimental therapy" to "established curative option." The simultaneous signal of a 21% second primary cancer rate adds critical long-term safety context that will reshape survivorship monitoring. Despite a small sample (n=38), this is essentially the entire eligible cohort surviving to 10 years, making it the best evidence that can realistically exist at this time horizon. Why it matters: Thousands of patients with relapsed/refractory DLBCL and FL are now in or approaching the window where this data applies — and their oncologists can counsel them with genuine evidence of cure rather than hope.

#2 — Exercise vs Liraglutide Vascular RCT | Impact 8.75 | 🟢 In the era of GLP-1RA prescription surges, this RCT delivers a pointed message: liraglutide alone does not improve vascular structure or systemic inflammation during weight maintenance — exercise does. The pre-specified design in Nature Metabolism gives this finding methodological credibility that a post-hoc analysis could not. The implications land squarely in primary care, where GLP-1RA prescriptions are often written without exercise counseling. Carotid IMT reduction is not a soft endpoint — it's a validated surrogate for atherosclerotic burden. Why it matters: With hundreds of millions on or considering GLP-1RAs, this finding argues urgently that exercise co-prescription is not optional if vascular risk reduction is a clinical goal.

#3 — Talos Automated Rare Disease Genomic Reanalysis | Impact 8.55 | 🟢🟡 Five percent sounds modest until you remember these are patients who had already exhausted conventional diagnostic pathways — families who had often been told there was no answer. Talos delivers answers to 1 in 20 of them using an automated, open-source pipeline that runs monthly on updated gene-disease evidence. The 90% sensitivity in trio analysis and 241 real diagnoses in 4,735 patients make this immediately deployable for any genomic diagnostic program. Why it matters: For rare disease families, a diagnosis ends the diagnostic odyssey, enables treatment decisions, guides reproductive counseling, and connects them to a disease community. This tool scales that possibility.

#4 — LUNA25 AI Lung Nodule Benchmark | Impact 8.33 | 🔴🟢 An AUC difference of 0.78 vs 0.70 translates to 12% more cancers caught at the same false-positive rate — or 20% fewer unnecessary follow-up procedures at the same detection rate. In lung cancer screening populations where millions of indeterminate nodules are generated annually, this performance gap has real mortality implications. The 65-radiologist comparison and external test set design make this among the most rigorous head-to-head AI-vs-human benchmarks published. Why it matters: Lung cancer kills ~1.8 million people per year globally; catching more malignant nodules earlier, with fewer false alarms, is directly life-saving.

#5 — Disparate Privacy Risks in Medical AI | Impact 8.05 | 🟡 This Nature study doesn't just show that medical AI can be attacked — it shows that the patients who are already underrepresented in training data face the greatest privacy exposure when those models are deployed. Aggregate privacy metrics are insufficient. Patient-level membership inference attacks succeed even when model-level statistics appear safe, and the disparity falls along familiar lines: race, insurance status, sex. Why it matters: Every hospital deploying a medical AI model trained on patient data is potentially exposing individual patients to re-identification — and the burden falls disproportionately on the most vulnerable.

#6 — Fludarabine vs Bendamustine CAR-T LD, CIBMTR | Impact 7.70 | 🟢 With n=5,256 patients across three commercial CAR-T products, this is the definitive real-world answer to a debate every CAR-T program has been having informally. Fludarabine wins on response; bendamustine wins on toxicity; OS converges at 1-2 years. This allows genuinely individualized decision-making based on patient risk profile. Why it matters: The choice of lymphodepletion chemotherapy is a modifiable variable at every CAR-T center — this data gives clinicians a robust evidence base to optimize it patient by patient.

#7 — ctDNA vs PET MRD Meta-analysis LBCL | Impact 7.18 | 🔴 The HR of 14 for undetectable ctDNA vs HR of 5 for PET negativity is a striking quantitative argument for ctDNA as the superior MRD tool in LBCL. The 95.7% 2-year PFS for patients achieving both endpoints provides a potential benchmark for response-adapted trial design. The small meta-analytic pool (3 studies, 367 patients) keeps confidence intervals wide, but the consistency across studies is notable. Why it matters: Better MRD tools mean better-designed clinical trials and, eventually, better-targeted de-escalation or intensification strategies for lymphoma patients.

#8 — FT14 Conditioning AML Phase II | Impact 7.15 | 🟠 An 81.7% 1-year LFS with near-zero NRM in a prospective multicenter setting addresses a genuine evidence gap for middle-aged AML transplant patients. The absence of a randomized comparator is a meaningful caveat, but for a Phase II signal-finding study, these are compelling numbers. Why it matters: Transplant-related mortality has historically been the barrier to curative-intent allo-HSCT in this age group — a conditioning regimen with near-zero NRM could expand access to potentially curative transplantation.

---

PHASE 4 — Deep Dive

---

[HOOK]

When a cancer treatment works, we call it effective. When it works and keeps working — when we can look ten years down the road and say the cancer simply hasn't come back — we call it something rarer: a cure. For patients with relapsed or refractory B-cell lymphoma, a devastating disease that had failed multiple rounds of treatment, that word has long been within reach but never quite grasped. Until now, the data just didn't exist to say it with confidence. Today, it does.

---

[THE DISCOVERY]

Researchers at the University of Pennsylvania led by Marco Ruella and colleagues followed 38 patients who received tisagenlecleucel — a personalized CAR-T cell therapy — for B-cell lymphomas, tracking them for a median of over 10 years. What they found was a plateau: a flat line on the survival curve. Among patients with diffuse large B-cell lymphoma (DLBCL), 32% were alive and lymphoma-free at 10 years. Among those with follicular lymphoma (FL), that number was 47%. And crucially, not a single patient relapsed after 5.4 years. Once you clear that threshold, the data suggests, you're out. The cancer does not come back.

Think of it like this: CAR-T therapy reprograms your own immune cells to hunt and eliminate lymphoma cells. For roughly one in three DLBCL patients and nearly one in two FL patients, those reprogrammed cells — or the immune memory they leave behind — appear to be doing their job indefinitely.

---

[THE SCIENCE BEHIND IT]

The study followed patients from the original tisagenlecleucel trial cohort — a prospective long-term follow-up with a median observation time of 10.1 years, published in the New England Journal of Medicine. That's as rigorous as long-term follow-up data gets. The researchers also found that persistence of the CAR-T transgene in the blood was associated with sustained response, and that B-cell aplasia — a sign that the CAR-T cells are still active — persisted in 44% of long-term responders. These mechanistic signals reinforce the clinical story.

The major limitation is sample size: only 38 evaluable patients. That's not a flaw — it reflects the reality that few patients from the original early-trial era have survived to this point and remained available for follow-up. But it means confidence intervals are wide and results should be interpreted as the best available signal, not the final statistical word.

---

[WHO THIS HELPS]

Most immediately, this data matters to patients with relapsed or refractory DLBCL or follicular lymphoma — cancers that have come back or stopped responding after standard treatments. These are patients who have often exhausted other options. It also matters to the oncologists counseling them, who can now speak about long-term cure probability with real evidence rather than cautious optimism. Patients weighing the significant short-term risks of CAR-T therapy — cytokine release syndrome, neurotoxicity, prolonged immune suppression — now have a clearer picture of the potential upside on the other side.

---

[THE REAL-WORLD IMPACT]

If widely adopted into counseling frameworks, this data changes the conversation in the clinic. Oncologists can now point to an actual 10-year landmark — a biologically meaningful threshold — when explaining what CAR-T therapy can achieve. It also has implications for survivorship programs: the 21% cumulative incidence of second primary cancers over 10 years means that long-term CAR-T survivors need active, structured monitoring for secondary malignancies, not just reassurance. And the persistent B-cell aplasia in a significant proportion of responders means ongoing infectious disease vigilance — a point reinforced by the companion Australian cohort study on long-term infection risk after CD19 CAR-T also published in this batch.

---

[WHAT WE STILL DON'T KNOW]

Several important questions remain. Can these survival curves be reproduced with the three commercial CAR-T products now in wide use — axicabtagene ciloleucel, lisocabtagene maraleucel, and tisagenlecleucel — which differ in their T-cell compositions and manufacturing? Do results hold across the broader, more heterogeneous real-world population who are older, frailer, and with more comorbidities than early trial participants? And can the 21% second primary cancer rate be mitigated — or is it an unavoidable cost of durable immune activation? Finally, the question of access looms large: CAR-T therapy remains one of the most expensive and logistically complex treatments in medicine, concentrated in academic centers.

---

[LIKELIHOOD OF MAKING A DIFFERENCE]

• Scientific Confidence: High
• Translation Speed: Already translated — this is long-term follow-up data on an approved, commercially available therapy
• Barrier Analysis:
  • Regulatory: None — tisagenlecleucel is already approved
  • Reimbursement: Major barrier; CAR-T therapies cost $400,000–$500,000+ in the U.S.; payer coverage remains inconsistent
  • Cost: The most significant barrier to equitable access globally
  • Infrastructure: Requires certified treatment centers; unavailable in most low- and middle-income countries
  • Awareness: This publication will accelerate clinician awareness and patient advocacy
  • Equity: Access is sharply inequitable by geography, insurance status, and performance status — durable cure data may intensify pressure for broader access but does not resolve the structural barriers

---

[CALL TO ACTION / CLOSING]

Ten years of follow-up data with no relapses after the five-year mark: for patients with relapsed B-cell lymphoma, that's not a promise — but it's the closest thing to one that evidence-based medicine can currently offer. The next frontier is making sure the patients who need this therapy can actually reach it.